Navigation Links
Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology
Date:1/3/2012

PLANTATION, Fla. and MOSCOW, Jan. 3, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC, a Maxwell Biotech portfolio company, jointly announced an agreement for cell line engineering and manufacturing of a monoclonal antibody expressed in a mammalian cell line. The monoclonal antibody will be engineered by GBI's collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in clinical trials as a potential treatment for renal cell carcinoma.

"This is an exciting project for us," noted Muctarr Sesay, PhD, Vice President of Process Development at GBI. "It truly represents 'one-stop-shopping' for our clients because we can take a client's cDNA, engineer the cell line with the help of one of our collaborative partners, Rafagen, who will provide us with three stable, high-producing clones, then we'll evaluate the clones and select the highest producer, create a Research Cell Bank and start manufacturing the antibody of interest."

"Our drug candidate OM-RCA-001 is a humanized monoclonal antibody and establishing a high producing cell line and creating a cell bank is one of the key stages of the product's development. We are pleased to partner with GBI in this, since GBI is known for its high quality services in this line of work," said Nikolay Golub, PhD, Project Manager at Maxwell Biotech Group where OncoMax is a portfolio company. "OM-RCA-001 blocks a specific target of kidney tumor cells, affecting the mechanisms of tumor progression and resistance. If all the clinical trials are successful we will have a novel biopharmaceutical that can be prescribed both as first-line treatment and as treatment in the second and subsequent lines after failure of other types of targeted therapy." 

About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies. For more information, please visit http://www.goodwinbio.com/.

About OncoMax LLC
OncoMax is a private biotechnological Russian company founded by Maxwell Biotech Group and funded by the Maxwell Biotech Venture Fund in 2010, a participant in the Technology Platform "Medicine of the Future" program and resident of the Skolkovo Innovation Center with a grant award from the Skolkovo Foundation. The mission of OncoMax is to develop and commercialize innovative therapies and diagnostics for oncology diseases. For more information, please visit: http://www.oncomax.com/.

About Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives, relying on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego.

MBG is investing in product development companies specializing in selected therapeutic and medical device categories. To date, MBG has established the portfolio companies of OncoMax (oncology), NeuroMax (CNS), MetaMax (oncology & metabolic diseases), Infectex (infectious diseases), CardioNova (cardiovascular diseases) and Photonics (novel lasers for medicine and dentistry). Products in these companies originated either from Russian scientists or were licensed for commercialization in Russia from international biopharma companies. For more information, please visit http://www.maxwellbio.com/.

For more information, please contact:

Goodwin Biotechnology:

Dave Cunningham

Director of Marketing

(954) 327-9639

DCunningham@goodwinbio.com

OncoMax:

Dr. Nikolay Golub

Project Manager
tel. +7 (495) 411-6992
golub@oncomax.ru

 


'/>"/>
SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
2. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
3. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
4. Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
5. Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics
6. Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape
7. HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
8. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
9. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
10. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
11. STELARA® Awarded 2011 Prix Galien USA in Best Biotechnology Product Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Antoine Dental Center is now offering various types ... replacement and act as a support for prosthetic teeth, such as crowns, bridges, or dentures. ... and becomes a sturdy, lasting new root for the tooth. , Several types of ...
(Date:6/26/2017)... ... 26, 2017 , ... The Centers for Advanced Orthopaedics (The ... Richard Robinson as chief operating officer (COO). In this role, Robinson brings more ... record of simplifying business processes and developing growth strategies to increase market share. ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... Antonio, TX (PRWEB) , ... June 26, 2017 ... ... physicians, their coding staff, and consumers are seeing lots of red these days. ... receive contain inaccurate charges that result from medical coding errors(1). Some studies point ...
(Date:6/26/2017)... WI (PRWEB) , ... June 26, 2017 , ... New ... consultations from Dr. Angela Cotey, with or without a referral. Dr. Cotey is a ... benefits of this preferred tooth replacement option. , Patients with missing teeth in Fitchburg, ...
Breaking Medicine News(10 mins):